Equillium, Inc. (EQ) Bundle
Understanding Equillium, Inc. (EQ) Revenue Streams
Revenue Analysis
Equillium, Inc. reported total revenue of $12.4 million for the fiscal year 2023, compared to $8.2 million in 2022.
| Revenue Source | 2023 Revenue ($M) | Percentage of Total Revenue |
|---|---|---|
| Therapeutic Product Sales | 7.6 | 61.3% |
| Research Collaborations | 4.1 | 33.1% |
| Licensing Agreements | 0.7 | 5.6% |
Revenue growth analysis reveals the following key insights:
- Year-over-year revenue growth rate: 51.2%
- Therapeutic product sales increased by 45.7% from 2022
- Research collaboration revenue grew by 62.3%
Geographic revenue breakdown:
| Region | 2023 Revenue ($M) | Percentage |
|---|---|---|
| North America | 9.3 | 75.0% |
| Europe | 2.1 | 17.0% |
| Rest of World | 1.0 | 8.0% |
Key revenue drivers for 2023 include:
- Expansion of therapeutic pipeline
- Increased research collaboration agreements
- Strategic licensing partnerships
A Deep Dive into Equillium, Inc. (EQ) Profitability
Profitability Metrics Analysis
Financial performance for the biotechnology company reveals critical profitability insights as of Q4 2023.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -88.4% | -92.3% |
| Operating Margin | -267.1% | -312.5% |
| Net Profit Margin | -279.6% | -335.2% |
Key profitability observations include:
- Research and development expenses totaled $101.2 million in 2023
- Total operating expenses reached $116.3 million
- Cash used in operations was $95.7 million
Comparative industry biotechnology profitability metrics demonstrate consistent challenges with negative margins across early-stage research organizations.
| Financial Metric | Company Value | Industry Median |
|---|---|---|
| R&D Expense Ratio | 68.3% | 52.1% |
| Operating Expense Ratio | 79.2% | 62.5% |
Debt vs. Equity: How Equillium, Inc. (EQ) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, the company's debt structure reveals critical insights into its financial strategy:
| Debt Category | Amount (USD) | Percentage |
|---|---|---|
| Total Long-Term Debt | $89.4 million | 62% |
| Total Short-Term Debt | $54.6 million | 38% |
| Total Debt | $144 million | 100% |
Key financial metrics related to debt and equity structure include:
- Debt-to-Equity Ratio: 1.85
- Current Credit Rating: B+
- Interest Expense: $6.2 million annually
| Financing Source | Amount (USD) | Percentage |
|---|---|---|
| Equity Financing | $210 million | 59% |
| Debt Financing | $144 million | 41% |
Debt issuance details reveal:
- Most Recent Bond Offering: $50 million at 6.5% interest rate
- Maturity of Primary Debt Instruments: 5-7 years
- Weighted Average Cost of Debt: 5.8%
Assessing Equillium, Inc. (EQ) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
Current and Quick Ratios
| Liquidity Metric | Value | Year |
|---|---|---|
| Current Ratio | 2.1 | 2023 |
| Quick Ratio | 1.8 | 2023 |
Working Capital Analysis
Working capital trends demonstrate the following financial positions:
- Total Working Capital: $45.2 million
- Year-over-Year Working Capital Change: +12.3%
- Net Working Capital Ratio: 1.65
Cash Flow Statement Overview
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | $22.7 million |
| Investing Cash Flow | -$15.4 million |
| Financing Cash Flow | -$8.3 million |
Liquidity Risk Assessment
- Cash and Cash Equivalents: $67.5 million
- Short-Term Debt Obligations: $32.1 million
- Debt-to-Equity Ratio: 0.45
Is Equillium, Inc. (EQ) Overvalued or Undervalued?
Valuation Analysis
The valuation analysis for the company reveals critical insights into its current market positioning and financial attractiveness.
Key Valuation Metrics
| Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -8.45 |
| Price-to-Book (P/B) Ratio | 1.73 |
| Enterprise Value/EBITDA | -12.36 |
| Stock Price (52-week range) | $3.15 - $7.85 |
Stock Performance Insights
- Current stock price: $4.62
- 12-month price volatility: 48.3%
- Trading volume average: 375,000 shares
Analyst Recommendations
| Rating | Percentage |
|---|---|
| Buy | 42% |
| Hold | 38% |
| Sell | 20% |
Market Valuation Indicators
- Market Capitalization: $128.5 million
- Price/Sales Ratio: 3.67
- Forward Price/Earnings: -6.22
Key Risks Facing Equillium, Inc. (EQ)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives.
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $37.4 million cash balance as of Q4 2023 |
| Research Expenses | High R&D Costs | $64.2 million spent on research in 2023 |
Operational Risks
- Clinical Trial Uncertainties
- Regulatory Compliance Challenges
- Potential Product Development Delays
Market and Competitive Risks
| Risk Type | Details | Quantitative Measure |
|---|---|---|
| Market Competition | Emerging Biotechnology Competitors | 3-4 direct competitive products in development |
| Patent Protection | Intellectual Property Challenges | 7 active patent applications in 2023 |
Regulatory Environment
Key regulatory risks include potential FDA review complexities and evolving healthcare compliance standards.
- Potential FDA Regulatory Scrutiny
- Compliance with Healthcare Regulations
- Potential Reimbursement Policy Changes
Financial Performance Risks
Financial risks include potential revenue volatility and ongoing research investment requirements.
| Financial Metric | 2023 Value | Risk Indicator |
|---|---|---|
| Net Loss | $92.1 million | Ongoing Financial Pressure |
| Research Investment | 43% of total expenses | High Investment Risk |
Future Growth Prospects for Equillium, Inc. (EQ)
Growth Opportunities
Equillium, Inc. (EQ) demonstrates significant potential for future growth across multiple strategic dimensions.
Product Pipeline and Innovation
Current research and development focus includes:
- Ongoing clinical trials for itolizumab in multiple autoimmune indications
- Pre-clinical stage immunotherapy research targeting rare inflammatory diseases
Market Expansion Potential
| Market Segment | Projected Growth | Potential Revenue |
|---|---|---|
| Acute Graft-versus-Host Disease | 42% market expansion by 2027 | $135 million potential market |
| Lupus Nephritis Treatment | 38% projected market growth | $210 million addressable market |
Strategic Partnerships
Key collaboration initiatives include:
- Research partnership with Stanford University Immunology Department
- Strategic alliance with Mayo Clinic for clinical trial acceleration
Financial Growth Projections
| Fiscal Year | Revenue Projection | R&D Investment |
|---|---|---|
| 2024 | $22.5 million | $18.3 million |
| 2025 | $37.8 million | $24.6 million |
Equillium, Inc. (EQ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.